In addition, we have reloaded our share purchase authorization program to allow for the Company to purchase up to $100 million of its outstanding shares.
In addition, as I'm sure that you are aware, last month President Biden issued broad sweeping vaccine and or testing requirements for all companies with more than 100 employees.
Net income for the quarter increased to $34.6 million or $1.82 per diluted share from $31.6 million or $1.66 per diluted share.
Consolidated revenues in our fourth quarter of 2021 were $465.3 million, an increase of 8.5% from $428.6 million a year ago.
At this time, we anticipate our full year revenues for fiscal 2022 will be between $1.92 billion and $1.945 billion.
For fiscal 2022, we further expect that our fully diluted earnings per share will be between $5.70 and $6.10.
